4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide and Myocardial-Ischemia

Preclinical studies indicate that minocycline protects against myocardial ischemia/reperfusion injury. In these studies, minocycline was administered before ischemia, which can rarely occur in clinical practice. The current study aimed to evaluate cardioprotection by minocycline treatment upon reperfusion.. Rabbits were subjected to myocardial ischemia/reperfusion injury and received either intravenous minocycline (n = 8) or saline (n = 8) upon reperfusion. Cardiac cell death was assessed by in vivo micro-SPECT/CT after injection of Indium-111-labeled 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (. Myocardial damage was visualized by micro-SPECT/CT imaging. Quantitative GSAO uptake (expressed as percent injected dose per gram, %ID/g) in the area at risk was lower in minocycline-treated animals than that in saline-treated control animals (0.32 ± 0.13% vs 0.48 ± 0.15%, P = 0.04). TUNEL staining confirmed the reduction of cell death in minocycline-treated animals.. This study demonstrates cardioprotection by minocycline in a clinically translatable protocol.

Topics: Animals; Arsenicals; Cell Death; Disease Models, Animal; Glutathione; Heart; Indium Radioisotopes; Minocycline; Multimodal Imaging; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Rabbits; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed